By employing public clinical data, the Kaplan–Meier survival analysis revealed that lung cancer patients with the high levels of AGO2 had a lower survival rate than those with the low levels of AGO2 (Fig. 6a), suggesting that the high expression levels of AGO2 may be a risk factor of lung cancer. This evidence concerns the gene AGO2 and lung cancer.